CrossRef Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S
Vial-and-syringe format
Renal protection with glucagon-like peptide type 1 receptor agonists In CVOTs of arGLP1 renal outcomes were prespecified as key secondary outcomes in 4 studies done with liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatide,58,59,63,64 or were collected as safety parameters in other studies.60 Overall, the prevalence of CKD stage 3 in these studies was low (2030%) (Table 1)
But the signal is real and the research community is paying attention to it
Key Benefits: Appetite Control: Helps reduce hunger and manage cravings throughout the day